A recently emerging class of anti-cancer therapies has focused on blocking the growth of new blood vessels or angiogenesis, which is necessary to support tumor growth. This proposal is based on a clinical clue provided by a unique population, individuals with Down syndrome, and seeks to define the molecular mechanisms underlying the cancer protection observed in the Down syndrome population. Epidemiological data suggests that a gene(s) present in 3 copies on chromosome 21 exerts a broad anti-cancer effect by controlling some common aspect of tumorigenesis. This proposal focuses on one promising candidate for this activity - the Down syndrome candidate region-1 (Dscr1) gene. The Dscr1 gene encodes a protein that blocks angiogenesis and specifically endothelial cell activation by negatively regulating VEGF-calcineurin signaling. We hypothesize that trisomic expression of Dscr1 in Down Syndrome suppresses tumor growth by attenuating VEGF-calcineurin-NFAT signaling and restricting tumor angiogenesis.
In Specific Aim 1, we will determine whether over-expression of DSCR1 is responsible for suppression of tumor growth in Down syndrome by using genetically engineered mouse models recently generated in my lab.
In Specific Aim 2 we will examine the role of thrombospondin-1 (TSP-1), a recently identified target in my lab of VEGF-calcineurin-NFAT signaling in endothelial cells, in modulating tumor angiogenesis. We will confirm the mechanism of Tsp-1 regulation by VEGF-calcineurin signaling and determine its role in modulating the pro-angiogenic effects of VEGF. We will also determine the consequences of Tsp-1 loss on VEGF signaling in endothelial cells.
In Specific Aim 3, we will determine the differential mechanisms by which DSCR1 and the pharmacologic calcineurin inhibitor cyclosporin A, block calcineurin function using a combination of biochemical and mutational approaches and transplantable tumor models in mice. The experiments proposed will use this clinical insight to derive mechanistic insight into how tumor angiogenesis and ultimately tumor growth can be inhibited or reversed by modulating calcineurin activity and function. Finally these studies will also establish whether Dscr1 is a valid target for anti-cancer intervention.

Public Health Relevance

The Down syndrome candidate region-1 (Dscr1) gene encodes a protein that blocks tumor angiogenesis and specifically endothelial cell activation. DSCR1 negatively regulates the VEGF-calcineurin pathway, an important signaling pathway in endothelial cells to promote angiogenesis. These studies will establish whether Dscr1 is a valid target for anti-cancer intervention which may lead to novel therapeutic strategies for suppressing tumor angiogenesis in all cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA118374-06
Application #
8462223
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Woodhouse, Elizabeth
Project Start
2009-07-01
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
6
Fiscal Year
2013
Total Cost
$272,447
Indirect Cost
$102,168
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Bhang, Dong Ha; Kim, Bang-Jin; Kim, Byung Gak et al. (2018) Testicular endothelial cells are a critical population in the germline stem cell niche. Nat Commun 9:4379
Yoon, Changhwan; Cho, Soo-Jeong; Chang, Kevin K et al. (2017) Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. Mol Cancer Res 15:1106-1116
Till, Jacob E; Yoon, Changhwan; Kim, Bang-Jin et al. (2017) Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression. Cancer Res 77:5349-5359
Till, Jacob E; Yoon, Sam S; Ryeom, Sandra (2017) E-cadherin and K-ras: implications of a newly developed model of gastric cancer. Oncoscience 4:162-163
Baek, Kwan-Hyuck; Ryeom, Sandra (2017) Detection of Oncogene-Induced Senescence In Vivo. Methods Mol Biol 1534:185-198
Schadler, Keri L; Thomas, Nicholas J; Galie, Peter A et al. (2016) Tumor vessel normalization after aerobic exercise enhances chemotherapeutic efficacy. Oncotarget 7:65429-65440
Yoon, Changhwan; Cho, Soo-Jeong; Aksoy, B├╝lent Arman et al. (2016) Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clin Cancer Res 22:971-83
Lehman, Stacey L; Cerniglia, George J; Johannes, Gregg J et al. (2015) Translational Upregulation of an Individual p21Cip1 Transcript Variant by GCN2 Regulates Cell Proliferation and Survival under Nutrient Stress. PLoS Genet 11:e1005212
Lehman, Stacey L; Ryeom, Sandra; Koumenis, Constantinos (2015) Signaling through alternative Integrated Stress Response pathways compensates for GCN2 loss in a mouse model of soft tissue sarcoma. Sci Rep 5:11781
Casey, Stephanie C; Vaccari, Monica; Al-Mulla, Fahd et al. (2015) The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis 36 Suppl 1:S160-83

Showing the most recent 10 out of 23 publications